Clinical Trial

Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma

Study acronym: SCR-ESCC-01
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
SCR-ESCC-01 is a multicenter, randomized, phase II study aiming to investigate the benefit of early involvement of low-dose radiotherapy(LDRT) and conventionally fractionated radiotherapy(CFRT) in the first-line anti-PD-1 based treatment of metastatic ESCC. It begins with a safety run-in phase, followed by a randomized controlled comparison against standard immunochemotherapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-08-03.
Trial Details
NCT Number NCT05978193
Lead Sponsor Shanghai Chest Hospital
Conditions Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Metastatic Esophageal Squamous Cell Carcinoma
Enrollment 100 participants
Start Date 2023-01-01
Primary Completion 2027-01 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-22